D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 130 Citations 134,246 569 World Ranking 1025 National Ranking 35

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Surgery
  • Cancer

The scientist’s investigation covers issues in Internal medicine, Surgery, Cardiology, Myocardial infarction and Percutaneous coronary intervention. His study in Placebo extends to Internal medicine with its themes. His biological study spans a wide range of topics, including Stroke and Hazard ratio.

His study in Myocardial infarction is interdisciplinary in nature, drawing from both Coronary artery disease and EuroSCORE. As part of one scientific family, Peter Jüni deals mainly with the area of Percutaneous coronary intervention, narrowing it down to issues related to the Acute coronary syndrome, and often Cumulative incidence. His Clinical trial research is multidisciplinary, incorporating elements of Psychological intervention, Research design, Intervention, Systematic review and Alternative medicine.

His most cited work include:

  • The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials (13036 citations)
  • ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation (5547 citations)
  • 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). (3314 citations)

What are the main themes of his work throughout his whole career to date?

Peter Jüni mainly focuses on Internal medicine, Cardiology, Surgery, Myocardial infarction and Percutaneous coronary intervention. His is involved in several facets of Internal medicine study, as is seen by his studies on Coronary artery disease, Randomized controlled trial, Conventional PCI, Hazard ratio and Clinical endpoint. His Randomized controlled trial research is multidisciplinary, incorporating perspectives in Psychological intervention, Clinical trial, Relative risk, Adverse effect and Meta-analysis.

His work investigates the relationship between Cardiology and topics such as Confidence interval that intersect with problems in Physical therapy. His work deals with themes such as Stroke and Angioplasty, which intersect with Surgery. Peter Jüni combines subjects such as Lower risk and Acute coronary syndrome with his study of Percutaneous coronary intervention.

He most often published in these fields:

  • Internal medicine (56.53%)
  • Cardiology (33.63%)
  • Surgery (31.28%)

What were the highlights of his more recent work (between 2019-2021)?

  • Internal medicine (56.53%)
  • Randomized controlled trial (25.40%)
  • Cardiology (33.63%)

In recent papers he was focusing on the following fields of study:

His primary scientific interests are in Internal medicine, Randomized controlled trial, Cardiology, Percutaneous coronary intervention and Myocardial infarction. His work on Ticagrelor, Clinical endpoint, Hazard ratio and Coronary artery disease as part of his general Internal medicine study is frequently connected to In patient, thereby bridging the divide between different branches of science. Peter Jüni has included themes like Empagliflozin and Placebo in his Coronary artery disease study.

His studies deal with areas such as Psychological intervention, Interquartile range, Clinical trial, Emergency medicine and Meta-analysis as well as Randomized controlled trial. His research brings together the fields of Confidence interval and Cardiology. His Percutaneous coronary intervention study also includes fields such as

  • Stent most often made with reference to Conventional PCI,
  • Stroke and related Cardiopulmonary bypass.

Between 2019 and 2021, his most popular works were:

  • 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASDThe Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD) (719 citations)
  • Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. (466 citations)
  • 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. (246 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Surgery
  • Disease

Peter Jüni mainly investigates Internal medicine, Randomized controlled trial, Adverse effect, Psychological intervention and Conventional PCI. His work is connected to Ticagrelor, Myocardial infarction, Heart failure, Randomization and Hazard ratio, as a part of Internal medicine. His Randomized controlled trial research is multidisciplinary, relying on both Interquartile range, Clinical trial, Obesity, Intensive care medicine and Meta-analysis.

As part of the same scientific family, he usually focuses on Adverse effect, concentrating on Placebo and intersecting with Breast feeding, Respiratory failure and Revascularization. His Conventional PCI study combines topics from a wide range of disciplines, such as Coronary artery disease, Clinical endpoint and Percutaneous coronary intervention. His Acute coronary syndrome study is related to the wider topic of Cardiology.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials

Julian P T Higgins;Douglas G Altman;Peter C Gøtzsche;Peter Jüni.
BMJ (2011)

16260 Citations

ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation

Stefan K. James;Dan Atar;Luigi P. Badano;Carina Blomstrom Lundqvist.
European Heart Journal (2012)

8910 Citations

2014 ESC/EACTS Guidelines on myocardial revascularization

Stephan Windecker;Philippe Kolh;Fernando Alfonso;Jean-Philippe Collet.
Kardiologia Polska (2014)

4961 Citations

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.

Jonathan A. C. Sterne;Miguel A Hernan;Barnaby C Reeves;Jelena Savovic;Jelena Savovic.
BMJ (2016)

3727 Citations

2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).

Stephan Windecker;Philippe Kolh;Fernando Alfonso;Jean-Philippe Collet.
European Journal of Cardio-Thoracic Surgery (2014)

3314 Citations

SYSTEMATIC REVIEWS IN HEALTH CARE: ASSESSING THE QUALITY OF CONTROLLED CLINICAL TRIALS

Peter Jüni;Douglas G Altman;Matthias Egger.
BMJ (2001)

2738 Citations

Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease

Bernard De Bruyne;Bindu Kalesan;Emanuele Barbato;Zsolt Piroth.
The New England Journal of Medicine (2012)

2266 Citations

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study.

Lesley Wood;Matthias Egger;Lise Lotte Gluud;Kenneth F Schulz.
BMJ (2008)

2235 Citations

The hazards of scoring the quality of clinical trials for meta-analysis.

Peter Jüni;Anne Witschi;Ralph Bloch;Matthias Egger.
JAMA (1999)

2154 Citations

Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study

Joost Daemen;Peter Wenaweser;Keiichi Tsuchida;Linda Abrecht.
The Lancet (2007)

2122 Citations

Editorial Boards

Trials
(Impact Factor: 2.728)

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Peter Jüni

Patrick W. Serruys

Patrick W. Serruys

National University of Ireland, Galway

Publications: 547

Stephan Windecker

Stephan Windecker

University of Bern

Publications: 373

Christian Gluud

Christian Gluud

Copenhagen Trial Unit

Publications: 268

Roxana Mehran

Roxana Mehran

Icahn School of Medicine at Mount Sinai

Publications: 255

Thomas F. Lüscher

Thomas F. Lüscher

University of Zurich

Publications: 253

Marco Valgimigli

Marco Valgimigli

University of Bern

Publications: 252

Adnan Kastrati

Adnan Kastrati

Technical University of Munich

Publications: 246

Gregg W. Stone

Gregg W. Stone

Columbia University Medical Center

Publications: 226

Antonio Colombo

Antonio Colombo

Vita-Salute San Raffaele University

Publications: 205

Deepak L. Bhatt

Deepak L. Bhatt

Brigham and Women's Hospital

Publications: 202

Davide Capodanno

Davide Capodanno

University of Catania

Publications: 173

Ron Waksman

Ron Waksman

MedStar Washington Hospital Center

Publications: 169

Seung-Jung Park

Seung-Jung Park

University of Ulsan

Publications: 169

Robert A. Byrne

Robert A. Byrne

Royal College of Surgeons in Ireland

Publications: 165

William Wijns

William Wijns

National University of Ireland, Galway

Publications: 164

Yangsoo Jang

Yangsoo Jang

Yonsei University

Publications: 160

Something went wrong. Please try again later.